Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Dec 1;50(12):1143-1148.
doi: 10.1097/DSS.0000000000004315. Epub 2024 Jul 5.

Prospective Clinical Trial Demonstrating the Efficacy of Hyaluronic Acid Filler for the Improvement of Atrophic Facial Scars up to 2 years

Robyn Siperstein  1   2 , Elizabeth Nestor  2 , Suzanne Meran  2
Affiliations
Randomized Controlled Trial

Prospective Clinical Trial Demonstrating the Efficacy of Hyaluronic Acid Filler for the Improvement of Atrophic Facial Scars up to 2 years

Robyn Siperstein et al. Dermatol Surg. .

Abstract

Background: Hyaluronic acid (HA) filler longevity has been studied for wrinkles. However, its long-term use for treating atrophic facial scars has not yet been analyzed in long-term prospective studies.

Objective: Analyze the safety and duration of a HA filler for the use in atrophic scars.

Materials and methods: Fifteen subjects received VYC-17.5L in atrophic scars on 1 randomized cheek and saline on the other, with 1 optional touch-up treatment and crossover after the short-term trial. Grading for this long-term extension was done on Day 720, using the Global Aesthetic Improvement Scale (GAIS) and the Quantitative Global Scarring Grading System.

Results: On Day 720, a live blind evaluator rated the VYC-17.5L assigned side as having significant reduction in scar severity (-7.2 [t(22) = -6.01, p = .00009]) and number of scars (-8.8 [t(22) = -6.25, p = .00006]) as compared with baseline. There was no significant difference in the results from Day 120 to Day 720. Ninety-two percent (11/12) of subjects reported improvement (GAIS), were satisfied with the treatment, thought it looked natural, and had fewer side effects than expected. There were no persistent or late-onset side effects.

Conclusion: VYC-17.5L improved rolling atrophic facial scars, and the results were sustained throughout the 2-year trial without side effects.

PubMed Disclaimer

Conflict of interest statement

The authors have indicated no significant interest with commercial supporters.

Figures

Figure 1.
Figure 1.
(A–C) Canfield Primos 3D photo-analysis of 46-year-old man with atrophic scarring (A) before treatment and (B) 90 days after treatment with VYC-17.5L, and (C) over 2 years after treatment.
See this image and copyright information in PMC

References

    1. Karnik J, Baumann L, Bruce S, Callender V, et al. . A double-blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars. J Am Acad Dermatol 2014;71:77–83. - PubMed
    1. Artzi O, Cohen S, Koren A, Niv R, et al. . Dual-plane hyaluronic acid treatment for atrophic acne scars. J Cosmet Dermatol 2020;19:69–74. - PubMed
    1. Halachmi S, Ben Amitai D, Lapidoth M. Treatment of acne scars with hyaluronic acid: an improved approach. J Drugs Dermatol 2013;12:e121–3. - PubMed
    1. Goodman GJ, Van Den Broek A. The modified tower vertical filler technique for the treatment of post-acne scarring. Australas J Dermatol 2016;57:19–23. - PubMed
    1. Kasper DA, Cohen JL, Saxena A, Morganroth GS. Fillers for postsurgical depressed scars after skin cancer reconstruction. J Drugs Dermatol 2008;7:486–7. - PubMed

Publication types